Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride.
暂无分享,去创建一个
Q. Trinh | M. Marchese | M. Paciotti | E. Cone | S. Basaria | N. Bhojani | D. Nguyen
[1] M. Voracek,et al. Association between suicide reporting in the media and suicide: systematic review and meta-analysis , 2020, BMJ.
[2] Q. Trinh,et al. Association of abiraterone and higher odds of cardiac complications compared to enzalutamide. , 2020 .
[3] M. Irwig. Finasteride and Suicide: A Postmarketing Case Series , 2020, Dermatology.
[4] D. Roden,et al. Cardiovascular Toxicities Associated With Ibrutinib. , 2019, Journal of the American College of Cardiology.
[5] C. Motosko,et al. Sexual dysfunction in men taking systemic dermatologic medication: A systematic review. , 2019, Journal of the American Academy of Dermatology.
[6] G. Gamble,et al. Evidence of a Media-Induced Nocebo Response Following a Nationwide Antidepressant Drug Switch , 2019, Clinical Psychology in Europe.
[7] K. Zorn,et al. Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update. , 2018, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[8] A. Avogaro,et al. Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions , 2018, Diabetes Therapy.
[9] E. Darwin,et al. Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review. , 2017, Dermatology online journal.
[10] G. Ricci,et al. Safety profile of H1‐antihistamines in pediatrics: an analysis based on data from VigiBase , 2017, Pharmacoepidemiology and drug safety.
[11] E. McArthur,et al. Association of Suicidality and Depression With 5&agr;-Reductase Inhibitors , 2017, JAMA internal medicine.
[12] T. Travison,et al. Characteristics of Men Who Report Persistent Sexual Symptoms After Finasteride Use for Hair Loss. , 2016, The Journal of clinical endocrinology and metabolism.
[13] Ruwen Böhm,et al. OpenVigil FDA – Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications , 2016, PloS one.
[14] M. Etminan,et al. Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low‐Dose Finasteride: A Pharmacovigilance Study , 2015, Pharmacotherapy.
[15] S. Belknap,et al. Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis. , 2015, JAMA dermatology.
[16] B. Chakraborty. Pharmacovigilance: A data mining approach to signal detection , 2015, Indian journal of pharmacology.
[17] J. Chudek,et al. Depressive symptoms in patients diagnosed with benign prostatic hyperplasia , 2015, International Urology and Nephrology.
[18] N. Tatonetti,et al. Stimulated Reporting: The Impact of US Food and Drug Administration-Issued Alerts on the Adverse Event Reporting System (FAERS) , 2014, Drug Safety.
[19] Alexander Bachmann,et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. , 2013, European urology.
[20] M. Irwig. Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. , 2012, The Journal of clinical psychiatry.
[21] Maryse Lapeyre-Mestre,et al. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. , 2011, British journal of clinical pharmacology.
[22] A. Tosti,et al. Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men , 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[23] M. Irwig,et al. Persistent sexual side effects of finasteride for male pattern hair loss. , 2011, The journal of sexual medicine.
[24] John T. Wei,et al. Update on AUA guideline on the management of benign prostatic hyperplasia. , 2011, The Journal of urology.
[25] A. Traish,et al. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. , 2011, The journal of sexual medicine.
[26] A. Tosti,et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents , 2011, The British journal of dermatology.
[27] A. Bate,et al. Quantitative signal detection using spontaneous ADR reporting , 2009, Pharmacoepidemiology and drug safety.
[28] P. Habibollahi,et al. BMC Clinical Pharmacology BioMed Central Research article , 2006 .
[29] B. Dubrovsky. Neurosteroids, neuroactive steroids, and symptoms of affective disorders , 2006, Pharmacology Biochemistry and Behavior.
[30] Kenneth J Rothman,et al. The reporting odds ratio and its advantages over the proportional reporting ratio , 2004, Pharmacoepidemiology and drug safety.
[31] G. Cunningham,et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. , 2004, The Journal of clinical endocrinology and metabolism.
[32] J. Lynch,et al. Epidemiologic evidence for the relation between socioeconomic status and depression, obesity, and diabetes. , 2002, Journal of psychosomatic research.
[33] P. Boyle,et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. , 2002, Urology.
[34] A. Hoes,et al. Non-sedating antihistamine drugs and cardiac arrhythmias -- biased risk estimates from spontaneous reporting systems? , 2002, British journal of clinical pharmacology.
[35] William DuMouchel,et al. Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System , 1999 .
[36] A. Guidotti,et al. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[37] L. George,et al. Social Support and the Outcome of Major Depression , 1989, British Journal of Psychiatry.
[38] J. Nickel. Comparison of clinical trials with finasteride and dutasteride. , 2004, Reviews in urology.
[39] E. Puijenbroek,et al. Application of Quantitative Signal Detection in the Dutch Spontaneous Reporting System for Adverse Drug Reactions , 2003, Drug safety.